Navigation Links
Epizyme's EPZ-5676 DOT1L Inhibitor Demonstrates Encouraging Initial Findings in an Ongoing Phase 1 Dose Escalation Study
Date:11/14/2013

CAMBRIDGE, Mass., Nov. 14, 2013 /PRNewswire/ --

  • Four dose cohorts (12, 24, 36 and 54 mg/m2/day) completed (16 patients, 8 with acute leukemia with MLL-r) with 21-day on/7-day off administration schedule
  • Observations to date include:
    • No dose-limiting toxicities; maximum tolerated dose (MTD) not reached
    • Treatment effects, consistent with genetically defined therapeutic mechanism of action, observed in 4 of 8 acute leukemia patients with MLL-rearrangement (MLL-r); no effects observed in non-MLL-r patients
    • Dose-proportional exposure
    • Dose- and time-dependent methyl mark inhibition
  • Plan to initiate Phase 1 MLL-r only expansion stage in December 2013 starting at an 80 mg/m2/day uninterrupted treatment schedule, continued dose escalation possible
  • Epizyme will host a conference call and live audio webcast today at 8:30 a.m. ET to discuss these data; slides will be available on www.epizyme.com prior to call

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced initial findings from an ongoing Phase 1 study of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT) being developed for the treatment of acute leukemia with alterations in the MLL gene.

"EPZ-5676 is a first-in-class inhibitor of the DOT1L HMT, and we are very pleased with the findings to date in the dose escalation stage of the ongoing two-stage Phase 1 study," said Robert J. Gould, Ph.D., chief executive officer, Epizyme. "The safety,
'/>"/>

SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Epizyme, Inc. Granted Notice of Allowance of Patent for EPZ-5676
2. Epizyme Receives Orphan Drug Designation for EPZ-5676
3. Epizyme, Inc. to Present Pre-Clinical Data on DOT1L and EZH2 Inhibitor Programs at the 55th ASH Annual Meeting
4. Epizyme to Partner to Develop DOT1L Companion Diagnostic
5. 3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. MEI Pharmas Mitochondrial Inhibitor ME-344 Shows Preliminary Evidence of Single-Agent Activity in First-in-Human Clinical Study
7. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
8. MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor
9. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
10. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
11. Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Today the U.S. Food ... Bexsero® for the prevention of serogroup B meningococcal ... and Pfizer,s vaccine Trumenba®, which received FDA approval in ... this devastating disease. "I have heard ...
(Date:1/23/2015)... analysis of Centers for Medicare and Medicaid Services, (CMS) ... percent of seniors chose lower-cost preferred pharmacy plans that ... The findings were released by Drug Channels . ... of Medicare Part D," said Pharmaceutical Care Management Association ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... Cord Blood America, Inc . ( http://www.cordblood-america.com ) (OTC ... stem cell preservation company focused on bringing the ... internationally, announced today a Special Meeting of its shareholders on ... reverse stock split of one share for each 500 outstanding ...
... Calif., Feb. 10, 2011 PRO-DEX, INC. (Nasdaq: ... quarter and six months ended December 31, 2010. ... 8% to $6.2 million from $5.7 million for the corresponding ... the Company,s medical device products to its largest customer, and ...
Cached Medicine Technology:Cord Blood America Announces Special Shareholder Meeting 2Cord Blood America Announces Special Shareholder Meeting 3Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 2Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 3Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 4Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 5Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 6Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 7
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... TripAdvisor as the number one best large hotel for families ... world for their annual Travelers’ Choice Awards. , TripAdvisor ... website is home to millions of unbiased and honest traveler ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many ... it on Facebook, Twitter, and Pinterest. The fans will have ... a lottery every week. , Moreover, the company has extended ... Angelweddingdress homepage for more information. , Angelweddingdress ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... health, social skills in the process, experts say , FRIDAY, ... mean days spent at the beach or lake, afternoon bike ... is more likely to be lived in the not-so-great indoors, ... "human" contact. , The indoor child phenomenon concerns health experts ...
... A twice weekly hip strengthening regimen performed for six ... some cases eliminating -- knee pain referred to as ... study by Tracy Dierks, assistant professor in the Department ... based on the theory that stronger hips would correct ...
... ... better ROI , ... Rochester, NY and Piscataway NJ (PRWEB) June 4, 2010 -- UniteU Technologies, Inc., a ... optimizing solutions for online stores, are announcing the availability of Filtered Navigation Search Express ...
... Theurer Cancer Center at Hackensack University Medical Center announced ... the American Society of Clinical Oncology (ASCO) annual meeting ... Research highlights include a comparison of first-line treatments for ... of a new genetically engineered cancer therapy, and the ...
... Blood Institute (NHLBI) has stopped a clinical trial evaluating a ... children with sickle cell anemia and iron overload because of ... than the existing treatment. The 26-site trial, Stroke ... between the ages of 5 and 18 who had already ...
... role in the aging process appears to play a role ... according to researchers from the Center for Stem Cell Biology ... Jefferson University. In the study, published online in ... protein interaction that controls the silencing of Oct4, a key ...
Cached Medicine News:Health News:Move Childhood Back Outdoors This Summer 2Health News:Move Childhood Back Outdoors This Summer 3Health News:Hip exercises found effective at reducing, eliminating common knee pain in runners 2Health News:UniteU and Celebros Launch Dynamic Cross-Sell and New Version of Filtered Navigation Search 2Health News:UniteU and Celebros Launch Dynamic Cross-Sell and New Version of Filtered Navigation Search 3Health News:John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting 2Health News:John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting 3Health News:John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting 4Health News:Stroke prevention study in children with sickle cell anemia, iron overload stopped early 2Health News:Stroke prevention study in children with sickle cell anemia, iron overload stopped early 3Health News:Gene related to aging plays role in stem cell differentiation 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: